Abstract
Purpose
Sex steroids play a key role on male bone homeostasis and body composition (BC), their role in men living with HIV (MLWH) is less recognized. This study aimed at investigating the prevalence of low BMD, sarcopenia, and sarcopenic obesity (SO) and their relationship with sex steroids in MLWH aged < 50.
Methods
Prospective, cross-sectional, observational study on MLWH younger than 50 (median age 47.0 years). BC and BMD were evaluated with DXA. Two different definitions of sarcopenia were applied: appendicular lean mass/height2 (ALMI) < 7.26 kg/m2 or appendicular lean mass/body weight (ALM/W) < 28.27%. Low BMD was defined for Z-score < −2.0. Sarcopenia coupled with obesity identified SO. Serum total testosterone (T) and estradiol (E2) were measured by LC–MS/MS; free testosterone (cFT) was calculated by Vermeulen equation.
Results
Sarcopenia was detected in 107 (34.9%) and 44 (14.3%) out of 307 MLWH according to ALMI and ALM/W, respectively. The prevalence of SO was similar by using both ALMI (11.4%) and ALM/W (12.4%). Sarcopenic and SO MLWH had lower total T and cFT in both the definition for sarcopenia. BMD was reduced in 43/307 (14.0%). Serum E2 < 18 pg/mL was an independent contributing factor for sarcopenia, SO, and low BMD.
Conclusions
T and E2 are important determinants of BC even in MLWH. This is among the first studies investigating the distribution of obesity phenotypes and the prevalence of SO among MLWH showing that SO is present in 11–12% of enrolled MLWH regardless of the definition used. However, deep differences emerged using two different diagnostic definitions.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The clinical picture of men living with HIV (MLWH) has notably evolved thanks to the improvement in antiretroviral therapies (ART) [1, 2]. As life expectancy in MLWH has increased [3], the clinical management of HIV has moved from the sole control of the disease also to the prevention and treatment of non-infectious comorbidities related to ART and aging [4], and sustain of health related quality of life. Many of these chronic comorbidities are frequent even in the general population but they prematurely occur in MLWH [5, 6].
Hypogonadism, osteoporosis, high risk of fractures, and changes in body composition are common HIV-related comorbidities [7,8,9,10,11,12]. Otherwise, sex steroids, particularly testosterone (T) and estradiol (E2), are factors able to strongly influence bone mass and body composition [13,14,15,16,17]. Beyond low serum T and low BMD, changes in body composition have been linked to HIV infection and treatment since the ‘80s. Even though new ARTs have fewer adverse effects and the magnitude of lipodystrophy appears to have decreased [18], sarcopenia, defined as reduced muscle mass, continues to be reported in MLWH [19, 20]. Additionally, sarcopenic obesity is a new construct of obesity in older adults who have high adiposity coupled with low muscle mass. Recent reviews have highlighted the impact of sarcopenic obesity on general health outcomes, cardiometabolic impairment, and mortality in the general population [21], but data in MLWH are scanty [22]. Furthermore, diagnostic criteria for sarcopenia changed throughout the years and different operational definitions are currently available; to date, there is no global consensus on which criteria to use for both sarcopenia and sarcopenic obesity even though consensus on this issue are becoming available [23, 24].
Although the etiology of such gonadal and musculoskeletal changes remains partly understood, either hypogonadism, osteoporosis, or sarcopenia maybe strictly interrelated in MLWH [8, 9]. As a matter of fact, androgen exposure (of which serum T levels might reflective) be directly associated with bone tissue, fat and lean mass in MLWH [25] and low BMD and sarcopenia are correlated in both men and women [26]. In line with this findings, emerging evidence confirms the mutual relationship among comorbidities, health status, and sex steroids in MLWH [25, 27, 28] as well as in male general population [29,30,31,32]. New insights have been recently added in this topic proposing HIV-related hypogonadism as a form of functional hypogonadism secondary to frailty and chronic comorbidities [25, 28]. However, the vicious circle between gonadal function, body composition and bone health remains to be fully elucidated in MLWH, especially in the young-to-middle age. With this in view, the aim of this study was to prospectively explore the relationship between serum sex steroids by the gold standard technology, body composition, and bone health status in a cohort of MLWH younger than 50 years. Secondary aims were to report the prevalence of sarcopenia, sarcopenic obesity and low BMD and to detect possible factors associated with these conditions.
Methods
Study design and participants
This was a cross-sectional observational study of prospectively collected data from May 2013 to December 2017, enrolling MLWH attending the Modena HIV Metabolic Clinic (MHMC) as previously described [25].
Inclusion criteria were a documented HIV-infection on ART treatment, age 18–50 years and written informed consent. In order to avoid the overlap with hypogonadism due to aging, the limit of age for enrolment was per protocol fixed below or equal to 50 years. Exclusion criteria were: severe liver or renal insufficiency, active malignancy, acquired immunodeficiency syndrome (AIDS), endocrine disease (pituitary, thyroid, testicular diseases), any medication that could interfere with gonadal function as well as any previous treatment involving pituitary region (surgery, radiotherapy).
A total of 319 MLWH were assessed for eligibility, 3 were excluded from the study (1 patient with severe liver insufficiency; 1 patient with sever chronic kidney disease; 1 patient with prior androgen treatment). Finally, 316 patients were enrolled.
Main outcome measures
Anthropometric evaluation and body composition assessment
Anthropometric measurements (weight, height, body mass index [BMI], waist, hip, and waist/hip ratio) were recorded at the time of the examination. Weight was measured after at least a 5-h fast by analogical balance and height by stadiometer. Waist and hip circumferences were measured as the average of 3 measurements. BMI was calculated as body weight (kilograms) divided by the square of height (square meters). A whole body composition assessment and measurement of BMD were both obtained by Dual-Energy X-ray Absorptiometry (DXA) (DXA, Hologic-QDR-2000 densitometer, Inc., Waltham, MA) according to standardized procedures [33, 34]. Precision error rates for the QDR 2000 were of 3% for the measurement of fat mass, and 1.5% for fat-free mass. DEXA underwent calibration daily to ensure accurate BMD measurements using an anthropometric phantom.
As a consensus for defining sarcopenia is lacking, we adopted two different operational definitions to diagnose sarcopenia: i) ALMI: appendicular lean mass index (appendicular lean mass/height2) with a cut off for sarcopenia of < 7.26 kg/m2 according to Baumgartner’s criteria [35]; ii) ALM/W: appendicular lean mass/body weight with a cut off for sarcopenia of < 28.27% as suggested by the recent European consensus statement [23, 36]. While ALMI is currently the most used index in the setting of MLWH [37], the application of ALM/W is catching on for the definition of sarcopenia in the general population [23]. DXA parameters were missing in 9 patients that were excluded from the analysis.
Obesity was defined as BMI ≥ 30 kg/m2 [38] and/or fat mass > 26% in men aged 20–39 and > 28% in men aged 40–50 [39]. According to BMI, men were further classified as underweight (< 18.5 kg/m2) and normal (18.5–25 kg/m2). Based on the combination of BMI and body fat mass, patients were classified into the following obesity phenotypes: i) normal: BMI 18.5–25 kg/m2 and body fat percentage < 26% or < 28% depending on patients’ age; ii) overweight: BMI 25–30 kg/m2 and body fat percentage < 26% or < 28% depending on patients’ age; iii) hidden obese: BMI 18.5–30 kg/m2 and body fat percentage > 26% or > 28% depending on patients’ age; iv) overt obese: BMI ≥ 30 kg/m2 and body fat mass > 26% or > 28% depending on patients’ age; v) underweight: BMI < 18.5 kg/m2.
Finally, sarcopenic obesity was defined by the coupled presence of sarcopenia and obesity, each defined as described above [23, 36, 39].
BMD assessment
BMD was assessed by the same DXA methodology described above. BMD was measured at lumbar spine (L1 to L4) and hip (total and neck). Precision error rates for the QDR 2000 were 1% or less for BMD. DEXA underwent calibration daily to ensure accurate BMD measurements using an anthropometric phantom. BMD measured by DXA is expressed as an areal density in g/cm2. For age < 50 years a condition of low BMD was defined for Z-score < 2.0 at lumbar or femoral site.
Laboratory analyses
Blood samples were collected at 8:00 am after an overnight fasting by an intravenous cannula inserted into an antecubital vein. The blood samples were centrifuged, and the serum was stored at −20 °C until assayed.
All biochemical and hormonal measurements have been performed as previously described [25]. In detail, sex steroids (total T, E2, estrone [E1], and dihydrotestosterone [DHT]) were assayed by validated liquid chromatography-tandem mass spectrometry technique (LC–MS/MS) methods [40,41,42]. Of the 316 enrolled patients, 71 participants were missing E2 data. Free T was calculated (cFT) by using the validated Vermeulen equation [43, 44].
Sex Hormone-binding globulin (SHBG), serum luteinizing hormone (LH), follicle stimulating hormone (FSH), and prolactin (PRL) were assessed by chemiluminescent immunoassay, as previously described [25].
Demographic and clinical parameters
At the moment of the visit, all participants answered a structured questionnaire. The questionnaire contained demographic data (age) and clinical data (date of HIV diagnosis, history of fractures, history of comorbidities, medications in use, physical activity, smoking, and alcohol intake). Data related to HIV infection were obtained from the medical records of the participants.
For the definition of frailty index (FI), please refer to previous publications [25, 45].
Statistical analysis
The non-parametric Mann–Whitney U test was used for comparisons of continuous variables since they resulted not normally distributed at the Kolmogorov–Smirnov test. Categorical variables were compared by Pearson’s Chi-squared test.
Linear regression was used to examine the association between continuous variables; significant results were expressed through the R2 coefficient.
Ordinal logistic regression was used to determine contributing factors to sarcopenia, low BMD, and sarcopenic obesity. Proportional odds models were used to estimate the odds ratio (OR) for the risk/protective factors.
Statistical analyses were performed using the Statistical Package for the Social Sciences’ (SPSS) software for Windows (version 28.0; SPSS Inc, Chicago, IL). For all comparisons, p < 0.05 was considered statistically significant.
Results
A total of 307 consecutive MLWH were enrolled, with a median age of 47.0 years (range 25.2–50.5 years) and a median duration of HIV-infection of 16.2 years (range 1.1–35.4 years). For comprehensive characteristics of the 316 patients, see our previous publication [25].
Prevalence of sarcopenia and associated factors
Sarcopenia was detected in 107 (34.9%) and 44 (14.3%) MLWH according to ALMI and ALM/W, respectively (Table 1).
MLWH with sarcopenia by ALMI
MLWH with ALMI-sarcopenia presented with significantly lower BMI compared to those without sarcopenia (p < 0.001) (Table 1). As expected, patients with sarcopenia had lower lean mass assessed at arms, trunk, legs, and total body; notably, the amount of total body fat mass was higher in sarcopenia subgroup (p = 0.038) (Table 1).
Bone parameters significantly differed in relation to the presence of ALMI-based sarcopenia. First, BMD values were lower at any site (lumbar, total and neck hip, p range: < 0.001–0.018) in sarcopenic MLWH, although the prevalence of low BMD for age was similar comparing the 2 subgroups (Table 1). Hip BMD (total hip: p < 0.001, β = 0.222, R2 = 0.050; neck hip: p = 0.008, β = 0.152, R2 = 0.023) was directly associated with ALMI; no significant association was confirmed for lumbar BMD at the bivariate regression analysis.
Interesting differences were found comparing sex steroids between sarcopenic and non-sarcopenic subgroups. First, total T (p = 0.002), E2/T ratio (p = 0.017), and cFT (p = 0.002) were significantly lower in MLWH with sarcopenia than those without; conversely, SHBG was higher in sarcopenic MLWH (p = 0.006) (Table 1). No difference was found for levels of estrogens, gonadotropins, and DHT (Table 1). At the bivariate linear regression analysis, only E2/T (p = 0.001, β = 0.235, R2 = 0.055) and SHBG (p = 0.017, β =−0.137, R2 = 0.019) were confirmed to be significantly associated with ALMI in opposite direction (directly for E2/T and negatively for SHBG); no significant regression was found for total T, cFT and E2 levels.
As to other biochemical data, HOMA index (p = 0.017) were slightly lower in MLWH with sarcopenia, whereas no difference was found for either fasting glucose or HbA1c levels (Table 1).
With regard to HIV-related data, no significant difference was found for HIV duration, ART exposure, CD4 nadir and current CD4 (Table 1). Finally, smoking was more frequent in sarcopenic than non-sarcopenic MLWH (p < 0.001) (Table 1).
A multivariate logistic regression analysis was performed to identify risk factors for sarcopenia defined by ALMI. Co-variates were chosen including variables that at univariate analysis displayed p-value < 0.10. The multivariate analysis showed that higher BMI values were protective for sarcopenia (OR = 0.64; 95% CI 0.56–0.72; p < 0.001), whereas E2 below 18 pg/mL was an independent risk factor for sarcopenia (OR = 3.50; 95% CI 1.20–10.20; p = 0.022). On the contrary, SHBG, total T and E2/T ratio, years of HIV, BMD values, and smoking lost the statistical significance.
MLWH with sarcopenia by ALM/W
Patients with ALM/W-sarcopenia presented with significantly higher BMI and W/H ratio compared to those without sarcopenia (p < 0.001) (Table 1). As expected, patients with sarcopenia had lower lean mass at arms and total lean body percentage (p < 0.001); notably, the total amount and the percentage of total body fat mass together with the trunk fat mass were all higher in sarcopenia subgroup (p < 0.001) (Table 1).
Bone parameters did not differ in relation to the presence of sarcopenia at ALM/W. Accordingly, no significant association was found between ALM/W and either lumbar or hip BMD at the bivariate regression analysis.
The following changes in circulating sex steroids between MLWH with and without ALM/W-sarcopenia were found: serum total T (p = 0.001) and cFT (p < 0.001) were significantly lower in sarcopenic than non-sarcopenic MLWH while other sex hormones and SHBG did not differ between the two groups.
Among other biochemical parameters, insulin (p = 0.015) together with HOMA index (p = 0.017) were slightly lower in non-sarcopenic than sarcopenic MLWH, whereas no difference was found for neither fasting glucose nor HbA1c levels (Table 1).
With regard to HIV-related parameters, no significant difference was found for HIV duration, duration of ART exposure, CD4 nadir and current CD4 (Table 1).
No differences in terms of lifestyle factors, and comorbidities were found, whereas MLWH with sarcopenia reported a frailty index significantly worse than MLWH without sarcopenia (p < 0.001) (Table 1).
A multivariate logistic regression analysis was repeated to identify risk factors for ALM/W-based sarcopenia, higher BMI values were protective for sarcopenia (OR = 0.65; 95% CI 0.48–0.88; p = 0.006), whereas E2 below 18 pg/mL was an independent risk factor for (OR = 18.80; 95% CI 3.10–114.05; p = 0.002). On the contrary, total T, cFT, W/H, and frailty score did not enter in the model.
Prevalence of sarcopenic obesity and distribution of obesity phenotypes
Based on the two different operational definitions of sarcopenia, the prevalence of sarcopenic obesity was almost the same: in detail 11.4% (35 out of 307 MLWH) according to ALMI and 12.4% (38 out of 307 MLWH) according to ALM/W (Table 2).
MLWH presenting with sarcopenic obesity at ALMI were younger than those without sarcopenic obesity (p = 0.025) and they had a longer duration of infection (p = 0.045) (Table 2). Concerning sex steroids, serum E2 (p = 0.001), E1 (p = 0.005), total T (p = 0.017), and cFT (p = 0.004) were significantly lower in the subgroup of sarcopenic obesity compared to that without sarcopenic obesity according to ALMI (Table 2). However, the prevalence of hypogonadism did not significantly differ between sarcopenic and non-sarcopenic subgroups (5/35, 14.3% vs 27/272 9.9%; p = 0.427). Table 3 details differences in bone and body composition parameters between MLWH with biochemical hypogonadism (i.e. total T < 320 ng/mL and/or cFT < 64 pg/mL) and those eugonadal.
According to ALM/W, BMI and W/H (both p < 0.001) were higher in MLWH in patients with sarcopenic obesity, whereas no difference was found for age nor duration of infection (Table 2). The group of sarcopenic obesity considering the ALM/W had lower levels of total T (p = 0.001) and cFT (p < 0.001), but serum E2 did not significantly differ in this case (Table 2). Accordingly, the prevalence of hypogonadism (i.e. total T < 320 ng/dL and/or cFT < 64 pg/mL) was higher in the subgroup of sarcopenic obesity compared to the subgroup without sarcopenic obesity (9/38, 23.7% vs 23/269, 8.6%; p = 0.004).
We performed a multivariate regression analysis to identify risk factors for sarcopenic obesity. As for sarcopenia, serum E2 below 18 pg/mL was confirmed as a risk factor for sarcopenic obesity both considering ALMI (OR = 5.58; 95%CI 1.40–22.35; p = 0.015) and ALM/W (OR = 26.01; 95%CI 3.00–225.08; p = 0.003) together with the duration of HIV (ALMI: OR = 1.12; 95%CI 1.01–1.24; p = 0.039—ALM/W: OR = 1.23; 95%CI 1.07–1.42; p = 0.004). cFT entered the model as risk factor only for sarcopenic obesity obtained from ALMI (OR = q.29; 95%CI 1.01–1.63; p = 0.038) and BMI entered the model as protective factor only for sarcopenic obesity obtained from ALM/W (OR = 0.62; 95%CI 0.44–0.87; p = 0.006); no significance was found for total T, cFT, W/H, and frailty.
The distribution of patients based on body phenotype (defined by BMI and body fat mass) is shown in Fig. 1 in detail 11 patients out of 307 (3.6%) were classified as overt obese, 73 (23.8%) hidden obese, 40 (13.0%) overweight, 175 (57.0%) normal, and 8 (2.6%) underweight.
Distribution of the entire cohort according to the BMI and total fat mass percentage. BMI body mass index, Each dot corresponds to one subject. Horizontal and vertical dotted lines represent the cut-offs applied for BMI and fat mass percentage to distinguish the abovementioned conditions. Orange: underweight; Grey: normal; Yellow: overweight; Red: hidden obese; Blue: overt obese
Prevalence of low BMD and associated factors
BMD was normal in 264 MLWH (86.0%) and reduced in 43 (14.0%) MLWH (Table 3).
No difference was found for anthropometric variables (BMI, W/H) comparing MLWH with low and normal BMD (Table 4).
Among body composition parameters lean mass significantly differed in relation to BMD values. Indeed, lean mass assessed at trunk (p < 0.001), arms (p = 0.036), legs (p = 0.009), and total body (p = 0.001) was significantly lower in the subgroup of low BMD (Table 4); no difference was found for fat mass at any site. Furthermore, BMD values (lumbar, total hip and neck hip) were significantly associated with lean and fat mass assessed at total and trunk levels (p range: < 0.001–0.025) (Table 5).
Among serum sex steroids only the E2/T ratio was significantly lower in MLWH with low BMD compared to those with normal BMD (p = 0.023) (Table 4). However, at bivariate linear regression, no significant association was found for E2/T and BMD at any site.
Concerning other biochemical measurements related to mineral homeostasis, lifestyle habits, and HIV variables, parameters did not differ between low BMD and normal BMD subgroups, as well as lifestyle habits (Table 4).
At multivariate logistic regression analysis performed to identify risk factors for low BMD, the co-variates were chosen including variables that at univariate analysis displayed p-value < 0.10. This multivariate analysis showed that serum E2 below 18 pg/mL was the only independent risk factor for low BMD (OR = 3.06; 95%CI 1.03–9.07; p = 0.043). On the contrary, SHBG, total T and E2/T ratio, years of HIV, and sarcopenia lost the statistical significance.
Discussion
The current study provides evidence that, notwithstanding the notable improvement in medical conditions of this population allowed by novel therapies, loss of muscle mass and low BMD remain frequent findings in young adult MLWH. Furthermore, among sex steroids, both T and E2 are confirmed as important determinants of body composition in MLWH also since they resulted independently associated with sarcopenia and low BMD, respectively. These results corroborate our previous data concerning the strict connection between estrogens, body fat, and health status in MLWH [25]. In parallel, this is among the first studies investigating the distribution of obesity phenotypes and the prevalence of sarcopenic obesity among MLWH showing that sarcopenic obesity is present in 11–12% of enrolled MLWH regardless of the definition used, but deep differences emerged using two different diagnostic definitions. Considering the amount of fat mass, up to one forth of our cohort presents with hidden obesity, demonstrating a high prevalence of this condition in MLWH < 50.
Over the last decade, sarcopenia in MLWH drew the attention of researchers in this field. However, the low agreement between methods to assess and define this disease turn it challenging to compare different studies, both in MLWH and in the general population. Several operational definitions are used to diagnose sarcopenia and pre-sarcopenia, some including functionality analysis of muscle strength (EWGSOP2) [46] but not others (Baumgartner’s criteria) [23, 35]. Beyond this limitation in the diagnostic criteria, other factors make the prevalence of sarcopenia in MLWH heterogenous across studies: for instance, lean mass can be assessed by DXA or electrical bioimpedance (BIA), and different methods are used to assess physical performance. In our study the prevalence of sarcopenia significantly changed according to two different criteria used, being higher with ALMI than ALM/W. The 34.9% prevalence of sarcopenia we obtained by ALMI is slightly higher compared to previous studies [47,48,49,50,51,52] that used lean body mass as the only parameter to define sarcopenia, as in our case, with a pooled prevalence of 28.8% according to a recent metanalysis [37]. Otherwise, the 14.3% prevalence we obtained by ALM/W was lower than previous studies, but in line with a recent one showing a prevalence of 11.8% [53]. Differences between ALMI and ALM/W definitions of sarcopenia might be due to a different accuracy in identifying sarcopenia according to i) HIV status (MLWH vs uninfected men, ii) different phenotypes of sarcopenia (e.g. low muscle mass plus high BMI vs low muscle mass plus low BMD). Accordingly, in our study ALMI seems to better identify sarcopenic MLWH with low muscle and bone mass (osteosarcopenia), while ALMI/W better identify patients with low percentage of lean mass and increased percentage of fat mass (i.e. the sarcopenic obesity). Conversely, ALMI is most often used in HIV setting [37], while ALM/W is mainly used in HIV uninfected men [23, 24]. Criteria used for defining sarcopenia by anthropometry should be preferred in young to middle-aged men as in this age range muscle strength is rarely impaired. Accordingly, there is uncertainty about the use of muscle strength in sarcopenia diagnosis in MLWH and its use in young men may lead to underestimation of sarcopenia. Overall, studies that considered only muscle mass as criterion to define sarcopenia found higher prevalence compared to those that added muscle strength or muscle function [19, 37, 54]. Since sarcopenia is a recognized predictor of all-cause mortality [55, 56], frailty and increased hospitalization costs [57], this is a relevant finding that may have major implications for those aging with HIV and should be considered in raising awareness about this aspect among HIV health professionals.
In this study both serum total T and cFT were significantly lower in sarcopenic MLWH independently from the criterion used to define sarcopenia suggesting a potential role of T in ensuring adequate lean mass (both muscle and bone mass). This is in line with well-known physiological anabolic actions of androgens on body composition by acting directly on muscle and through their conversion to estrogens on bone [15, 16, 58, 59].
Although it has been estimated that MLWH presented sixfold greater odds of sarcopenia compared with matched controls of same age [37], sarcopenia remains largely underdiagnosed in the clinical care of MLWH. Indeed, HIV has been not yet identified as a contributing factor in the sarcopenia consensus and guidelines [46].
In this study the distribution of obesity phenotypes (overt, hidden, and apparent obesity) are quite different from those reported in a recent study among Japanese MLWH, with hidden obesity being detected in 46% of Konishi’s cohort and in 24% of our cohort [60]. Differences can be explained by the older age of the Asiatic cohort compared to ours and by the different cut off for fat mass used to define obesity (≥ 20% in Konishi et al. vs ≥ 26–28% in our study), as should be done in relation to patients’ race [23]. On the other hand, in the literature little is currently known about the prevalence of sarcopenic obesity among MLWH. In our MLWH cohort we found an overall prevalence of sarcopenic obesity of 11–12% regardless of the diagnostic criterion used for sarcopenia. Independently from the criteria used for defining sarcopenia, serum TT and cFT were both lower in MLWH with than in those without sarcopenic obesity confirming the importance of sex steroids in sarcopenic obesity [61]. Again, as discussed above for sarcopenia, sarcopenic obesity is also associated with a vast array of adverse health outcomes, including morbidity and mortality in older population without HIV [61, 62]; MLWH may experience many of these consequences more often than people aging without HIV. As such, sarcopenic obesity is expected to pose a major socioeconomic burden for MLWH. Thus, sarcopenic obesity diagnosis and development of intervention programs to prevent/treat this condition in MLWH are advocated.
Strictly associated with the presence of sarcopenia is the finding of impaired BMD. Indeed, we demonstrate that low BMD defined as Z-score below −2 is highly prevalent among MLWH younger than 50, confirming data available in literature [63, 64]. Similar considerations that we made for loss of muscle mass can be drawn for low BMD, since these two conditions are strictly related. Accordingly, lean mass was significantly lower in MLWH with low than in those with normal BMD and lean mass was directly related to BMD in this study, confirming data available in literature in MLWH [51, 53] and general population [65]. Bone and muscle, in fact, closely interact with each other not only anatomically, but also chemically and metabolically. From a clinical standpoint, osteoporosis as well as sarcopenia is linked to negative outcomes such as falls, fractures, loss of function, frailty, and mortality increase, thus generating significant personal and socio-economic costs. Therefore, it has been proposed that when BMD loss is synchronic with decreased muscle mass, it should be interpreted as a single diagnosis of osteosarcopenia, which may be preventable and treatable [66]. This study first highlights and confirms the central role of sex steroids, estrogens rather than androgens, in the strict interconnection between bone, muscle, and adipose tissue. MLWH with low serum E2 (< 18 pg/mL) had threefold increased likelihood to develop sarcopenia and/or low BMD. The role of estrogen deficiency on low BMD has been previously demonstrated by our group in MLWH [63] as well as in male population [17, 67]. Furthermore, even a disproportional estrogens-androgens balance was found to be involved in the muscle and BMD loss, since MLWH with sarcopenia and with low BMD had lower E2/T ratio compared to non-sarcopenic and normal BMD subgroups, respectively. These findings reiterate our previous data adding further value to the deep involvement of sex steroids, particularly estrogens, in the vicious circle connecting bone, fat, and skeletal muscle [25] (Fig. 2). As a confirmation of the protective role of estrogens against sarcopenia and BMD loss, sex differences in muscle and strength loss in HIV cohorts have been already reported [52, 68,69,70]. At present, data about the role of E2 in the homeostasis of musculoskeletal system in males are not only few, but also conflicting; hence, estrogen deficiency in men and its consequences on muscle represents still a challenge both in research and clinical settings. Overall, literature speaks in favor of a direct relationship between serum E2 and muscle mass in men [71, 72] with a minority of studies showing opposite results [73].
Different speculations can be made to clarify pathophysiological mechanisms leading to the persistence of sarcopenia/osteoporosis in HIV setting nowadays. Fat infiltration, typical of both primary sarcopenia and HIV-related fat alterations, is associated to increased metabolic and immunological activity of the adipose tissue [18]. On the other hand, it is not clear whether this decrease in muscle and bone mass found in MLWH is different from that occurring in the general population due to aging. Indeed, aging is the primary cause of sarcopenia [46] and osteoporosis among healthy people. Since MLWH enrolled in this study were younger than 50 years, the high prevalence of both sarcopenia and sarcopenic obesity in our cohort supports an accentuated aging in these patients [1, 74, 75]; in addition, the effect of aging is further emerging in MLWH due to the progressive improvement of life expectancy.
Considering metabolic parameters, BMI, insulin levels and HOMA index present different behaviors according to the two classifications of sarcopenia. Indeed, BMI is known to not include information about loss of lean mass. Likewise, in the sarcopenia evaluation, the insulin levels appear to provide no additional information on the metabolic status of the subjects, remaining within the normal ranges in the entire sample. Furthermore, dividing the population according to the definition of sarcopenic obesity, the BMI resulted significantly higher in the group with sarcopenic obesity defined through the ALM/W criteria, while no differences has been described according to the ALMI formula. Lastly, sarcopenic obesity does not determine changes in the prevalence of diabetic or cardiovascular disease in our sample, considering both definition methods.
This study has strengths and limitations. This is a properly-designed study to investigate the gonadal function in MLWH in which measurement of total T, E2, DHT, and E1were obtained by the recommended analytical technology (LC–MS/MS) alongside SHBG in order to calculate free T that is recognized to be the most reliable biomarker to detect the gonadal status in these patients [58, 76, 77]. Other points of strength are the detailed study of body composition and the selection of young/middle-aged subjects in our cohort, that allowed us to downgrade and avoid the influence of physiological aging on both T levels and body composition changes. The lack of muscle functionality tests for the diagnosis of sarcopenia and DXA inability to quantify fat infiltration into muscle tissue represent limitations. This study does not allow establishing a cause-effect relationship among all these factors due to its cross-sectional design, but it helps in understanding factors associated to sarcopenia and low BMD; for this reason, the lack of a control group of HIV-uninfected men could be considered as a minor limit.
In conclusion, this study shows that sarcopenia and low BMD are common findings among MLWH younger than 50 years. Additionally, the prevalence of sarcopenic obesity and hidden obesity is high and it may be overlooked by weight measurement alone or BMI calculation with a consequent undermanagement of the increased cardiometabolic risk. Within the multidimensional network of factors leading to reduced BMD and lean mass, an imbalanced E2/TT ratio and low serum E2 (< 18 pg/mL) seem to be more relevant rather than TT alone.
In clinical practice the use of different criteria for the definition of sarcopenia (i.e. ALMI and ALM/W) in the setting of MLWH probably allows identifying different forms of sarcopenia since ALMI better characterize osteosarcopenia, while ALM/W leads to identification of sarcopenic obesity. Finally, the recognition of MLWH as vulnerable population who would benefit from an early diagnosis of sarcopenia is advocated for the clinical practice and future guidelines.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Guaraldi G, Milic J, Mussini C (2019) Aging with HIV. Curr HIV/AIDS Rep 16(6):475–481
Brothers TD, Kirkland S, Guaraldi G, Falutz J, Theou O, Johnston BL, Rockwood K (2014) Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis 210(8):1170–1179
Frank Tahvi D et al (2019) Global, regional, and national incidence, prevalence, and mortality of HIV,1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the global burden of diseases 2017. Injuries, and Risk Factors Study Lancet HIV 6(12):e831–e859
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D’Arminio Monforte A, D’Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F (2023) Pillars of long-term antiretroviral therapy success. Pharmacol Res 196:106898
Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53(11):1120–1126
Brothers TD, Rockwood K (2014) Biologic aging, frailty, and age-related disease in chronic HIV infection. Curr Opin HIV AIDS 9(4):412–418
Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, Diazzi C, Carli F, Carani C, Guaraldi G (2011) Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS ONE 6(12):e28512
Rochira V, Guaraldi G (2014) Hypogonadism in the HIV-infected man. Endocrinol Metab Clin North Am 43(3):709–730
Maffezzoni F, Porcelli T, Delbarba A, Pezzaioli LC, Properzi M, Cappelli C, Castelli F, Quiros-Roldan ME, Ferlin A (2020) Hypogonadism and bone health in men with HIV. Lancet HIV 7(11):e782–e790
Santi D, Spaggiari G, Vena W, Pizzocaro A, Maggi M, Rochira V, Corona G (2021) The prevalence of hypogonadism and the effectiveness of androgen administration on body composition in HIV-infected men: a meta-analysis. Cells. https://doi.org/10.3390/cells10082067
Goh SSL, Lai PSM, Tan ATB, Ponnampalavanar S (2018) Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int 29(3):595–613
Premaor MO, Compston JE (2018) The hidden burden of fractures in people living with HIV. JBMR Plus 2(5):247–256
Rochira V (2020). Late-onset hypogonadism: bone health andrology. https://doi.org/10.1111/andr.12827
Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW (2016) Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest 126(3):1114–1125
Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369(11):1011–1022
Isidori AM, Aversa A, Calogero A, Ferlin A, Francavilla S, Lanfranco F, Pivonello R, Rochira V, Corona G, Maggi M (2022) Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE). J Endocrinol Invest 45(12):2385–2403
Rochira V, Carani C (2023) Estrogens, 2000 Male Reproduction and Beyond. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA): MDText.com, Inc. Copyright © 2000–2023, MDText.com, Inc.; 2000 10 56-78
Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, Brown TT, Capeau J (2020) HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers 6(1):48
Dos-Santos-Quaresma MVL, Lima-Ribeiro SM (2022) Sarcopenia in persons living with HIV under antiretroviral therapy: literature review. AIDS Rev 24(1):1–15
Guimarães NS, Raposo MA, Greco D, Tupinambás U, Premaor MO (2022) People living with hiv, lean mass, and sarcopenia: a systematic review and meta-analysis. J Clin Densitom 25(1):113–123
Wannamethee SG, Atkins JL (2015) Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc 74(4):405–412
Milic J, Calza S, Cantergiani S, Albertini M, Gallerani A, Menozzi M, Barp N, Todisco V, Renzetti S, Motta F, Mussini C, Sebastiani G, Raggi P, Guaraldi G (2023) Sarcopenic obesity phenotypes in patients with HIV: implications for cardiovascular prevention and rehabilitation. Can J Cardiol
Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, Bauer JM, Boirie Y, Cruz-Jentoft AJ, Dicker D, Frara S, Frühbeck G, Genton L, Gepner Y, Giustina A, Gonzalez MC, Han HS, Heymsfield SB, Higashiguchi T, Laviano A, Lenzi A, Nyulasi I, Parrinello E, Poggiogalle E, Prado CM, Salvador J, Rolland Y, Santini F, Serlie MJ, Shi H, Sieber CC, Siervo M, Vettor R, Villareal DT, Volkert D, Yu J, Zamboni M, Barazzoni R (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr 41(4):990–1000
Gortan Cappellari G, Guillet C, Poggiogalle E, Ballesteros Pomar MD, Batsis JA, Boirie Y, Breton I, Frara S, Genton L, Gepner Y, Gonzalez MC, Heymsfield SB, Kiesswetter E, Laviano A, Prado CM, Santini F, Serlie MJ, Siervo M, Villareal DT, Volkert D, Voortman T, Weijs PJ, Zamboni M, Bischoff SC, Busetto L, Cederholm T, Barazzoni R, Donini LM (2023) Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) - Proceedings from the SOGLI consortium meeting in rome November 2022. Clin Nutr 42(5):687–699
De Vincentis S, Decaroli MC, Fanelli F, Diazzi C, Mezzullo M, Morini F, Bertani D, Milic J, Carli F, Cuomo G, Santi D, Tartaro G, Tagliavini S, De Santis MC, Roli L, Trenti T, Pagotto U, Guaraldi G, Rochira V (2021) Health status is related to testosterone, estrone and body fat: moving to functional hypogonadism in adult men with HIV. Eur J Endocrinol 184(1):107–122
Verschueren S, Gielen E, O’Neill TW, Pye SR, Adams JE, Ward KA, Wu FC, Szulc P, Laurent M, Claessens F, Vanderschueren D, Boonen S (2013) Sarcopenia and its relationship with bone mineral density in middle-aged and elderly European men. Osteoporos Int 24(1):87–98
Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella FJ Jr, Lake JE, Bui H, Kingsley L, Brown TT (2017) Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-related phenotype of men with or at risk for HIV infection. J Infect Dis 215(2):228–237
Rochira V, Diazzi C, Santi D, Brigante G, Ansaloni A, Decaroli MC, De Vincentis S, Stentarelli C, Zona S, Guaraldi G (2015) Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. Andrology 3(2):298–308
Hsu B, Cumming RG, Handelsman DJ (2018) Testosterone, frailty and physical function in older men. Expert Rev Endocrinol Metab 13(3):159–165
Hyde Z, Flicker L, Almeida OP, Hankey GJ, McCaul KA, Chubb SA, Yeap BB (2010) Low free testosterone predicts frailty in older men: the health in men study. J Clin Endocrinol Metab 95(7):3165–3172
Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, Clark RV, O’Donnell AB, McKinlay JB (2008) The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 56(5):831–839
Rastrelli G, Corona G, Maggi M (2020) Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl 22(3):265–273
Park YW, Heymsfield SB, Gallagher D (2002) Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord 26(7):978–983
Shepherd JA, Schousboe JT, Broy SB, Engelke K, Leslie WD (2015) Executive summary of the ISCD position development conference on advanced measures from DXA and QCT fracture prediction beyond BMD. J Clin Densitom 18(3):274–286
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763
Poggiogalle E, Lubrano C, Sergi G, Coin A, Gnessi L, Mariani S, Lenzi A, Donini LM (2016) Sarcopenic obesity and metabolic syndrome in adult caucasian subjects. J Nutr Health Aging 20(9):958–963
Oliveira VHF, Borsari AL, Webel AR, Erlandson KM, Deminice R (2020) Sarcopenia in people living with the human immunodeficiency virus: a systematic review and meta-analysis. Eur J Clin Nutr 74(7):1009–1021
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000),894:1–253
Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y (2000) Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 72(3):694–701
Fanelli F, Belluomo I, Di Lallo VD, Cuomo G, De Iasio R, Baccini M, Casadio E, Casetta B, Vicennati V, Gambineri A, Grossi G, Pasquali R, Pagotto U (2011) Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. Steroids 76(3):244–253
Mezzullo M, Pelusi C, Fazzini A, Repaci A, Di Dalmazi G, Gambineri A, Pagotto U, Fanelli F (2020) Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry. J Steroid Biochem Mol Biol 197:105538
Büttler RM, Martens F, Fanelli F, Pham HT, Kushnir MM, Janssen MJ, Owen L, Taylor AE, Soeborg T, Blankenstein MA, Heijboer AC (2015) Comparison of 7 Published LC-MS/MS methods for the simultaneous measurement of testosterone, androstenedione, and dehydroepiandrosterone in serum. Clin Chem 61(12):1475–1483
Keevil BG, Adaway J (2019) Assessment of free testosterone concentration. J Steroid Biochem Mol Biol 190:207–211
Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84(10):3666–3672
Guaraldi G, Brothers TD, Zona S, Stentarelli C, Carli F, Malagoli A, Santoro A, Menozzi M, Mussi C, Mussini C, Kirkland S, Falutz J, Rockwood K (2015) A frailty index predicts survival and incident multimorbidity independent of markers of HIV disease severity. AIDS 29(13):1633–1641
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(1):16–31
Buehring B, Kirchner E, Sun Z, Calabrese L (2012) The frequency of low muscle mass and its overlap with low bone mineral density and lipodystrophy in individuals with HIV–a pilot study using DXA total body composition analysis. J Clin Densitom 15(2):224–232
Dutta D, Sharma M, Bansal R, Sharma N, Garga UC, Anand A, Gaurav K (2017) Low skeletal mass is an important predictor of osteoporosis in HIV-infected men in India. Endokrynol Pol 68(6):642–651
Hawkins KL, Zhang L, Ng DK, Althoff KN, Palella FJ Jr, Kingsley LA, Jacobson LP, Margolick JB, Lake JE, Brown TT, Erlandson KM (2018) Abdominal obesity, sarcopenia, and osteoporosis are associated with frailty in men living with and without HIV. AIDS 32(10):1257–1266
Mialich MS, Dos Santos AP, da Silva BR, de Paula FJ, Jordão AA, Navarro AM (2017) Relationship between adiposity indices, lipodystrophy, and sarcopenia in HIV-positive individuals with and without lipodystrophy. J Clin Densitom 20(1):73–81
Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB (2013) Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr 63(2):209–215
Echeverría P, Bonjoch A, Puig J, Estany C, Ornelas A, Clotet B, Negredo E (2018) High prevalence of sarcopenia in HIV-infected individuals. Biomed Res Int 2018:5074923
Gregson CL, Madanhire T, Rehman A, Ferrand RA, Cappola AR, Tollman S, Mokoena T, Micklesfield LK, Wade AN, Fabian J (2022) Osteoporosis, rather than sarcopenia, is the predominant musculoskeletal disease in a rural south african community where human immunodeficiency virus prevalence is high: a cross-sectional study. J Bone Miner Res 37(2):244–255
Oliveira VHF, Borsari AL, Cárdenas JDG, Alves Junior CM, Castro NF, Marinello PC, Padilha CS, Webel AR, Erlandson KM, Deminice R (2021) Low agreement between initial and revised european consensus on definition and diagnosis of sarcopenia applied to people living with HIV. J Acquir Immune Defic Syndr 86(4):e106–e113
Liu P, Hao Q, Hai S, Wang H, Cao L, Dong B (2017) Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas 103:16–22
Scherzer R, Heymsfield SB, Lee D, Powderly WG, Tien PC, Bacchetti P, Shlipak MG, Grunfeld C (2011) Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 25(11):1405–1414
Sousa AS, Guerra RS, Fonseca I, Pichel F, Ferreira S, Amaral TF (2016) Financial impact of sarcopenia on hospitalization costs. Eur J Clin Nutr 70(9):1046–1051
Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA (2018) Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 103(5):1715–1744
Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63(3):280–293
Konishi K, Nakagawa H, Asaoka T, Kasamatsu Y, Goto T, Shirano M (2022) Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition. Medicine (Baltimore) 101(42):e31349
Batsis JA, Villareal DT (2018) Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 14(9):513–537
Roh E, Choi KM (2020) Health consequences of sarcopenic obesity: a narrative review. Front Endocrinol (Lausanne) 11:332
Santi D, Madeo B, Carli F, Zona S, Brigante G, Vescini F, Guaraldi G, Rochira V (2016) Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study. Osteoporos Int 27(3):1103–1114
Abreu JM, Nogueira ABB, Villela MM, Módolo DM, Panaro TC, Setubal S, Velarde LGC, Lima GAB, da Cruz Filho RA, Soares DV (2022) Low bone mass and vitamin D in Brazilian people living with HIV under antiretroviral therapy. Arch Osteoporos 17(1):40
Qin H, Jiao W (2022) Correlation of muscle mass and bone mineral density in the NHANES US general population, 2017–2018. Medicine (Baltimore) 101(39):e30735
Hirschfeld HP, Kinsella R, Duque G (2017) Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int 28(10):2781–2790
Rochira V, Antonio L, Vanderschueren D (2018) EAA clinical guideline on management of bone health in the andrological outpatient clinic. Andrology 6(2):272–285
Wasserman P, Segal-Maurer S, Rubin DS (2014) High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care 13(2):145–152
Yarasheski KE, Scherzer R, Kotler DP, Dobs AS, Tien PC, Lewis CE, Kronmal RA, Heymsfield SB, Bacchetti P, Grunfeld C (2011) Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. J Gerontol A Biol Sci Med Sci 66(3):332–340
Oliveira VH, Wiechmann SL, Narciso AM, Webel AR, Deminice R (2018) Muscle strength is impaired in men but not in women living with HIV taking antiretroviral therapy. Antivir Ther 23(1):11–19
Banica T, Verroken C, Reyns T, T’Sjoen G, Fiers T, Kaufman JM, Lapauw B (2023) Physiological declines in sex steroid exposure in relation to changes in body composition in healthy men-a prospective cohort study. Eur J Endocrinol 188(6):510–518
Vandenput L, Mellström D, Karlsson MK, Orwoll E, Labrie F, Ljunggren O, Ohlsson C (2010) Serum estradiol is associated with lean mass in elderly Swedish men. Eur J Endocrinol 162(4):737–745
Gielen E, O’Neill TW, Pye SR, Adams JE, Wu FC, Laurent MR, Claessens F, Ward KA, Boonen S, Bouillon R, Vanderschueren D, Verschueren S (2015) Endocrine determinants of incident sarcopenia in middle-aged and elderly European men. J Cachexia Sarcopenia Muscle 6(3):242–252
Guaraldi G, Rockwood K (2017) Geriatric-HIV Medicine Is Born. Clin Infect Dis 65(3):507–509
Martin J, Volberding P (2010) A field still in its infancy. Ann Intern Med. United States HIV and premature aging 153:477–479
Rochira V (2017) Hypogonadism in systemic diseases. In: Simoni M, Huhtaniemi I (eds) Endocrinology of the testis and male reproduction. Springer International Publishing, Cham, pp 1–51
Corona G, Goulis DG, Huhtaniemi I, Zitzmann M, Toppari J, Forti G, Vanderschueren D, Wu FC (2020) European academy of andrology (EAA) guidelines* on investigation, treatment and monitoring of functional hypogonadism in males. Andrology 2020(10):34–56
Acknowledgements
Authors are grateful to the Italian Ministry of University and Research for supporting the Department of Biomedical, Metabolic, and Neural Sciences (University of Modena and Reggio Emilia, Italy) in the context of the Departments of Excellence Programme.
Funding
Open access funding provided by Università degli Studi di Modena e Reggio Emilia within the CRUI-CARE Agreement.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by SDV, CG, FF, MCD, MM, MCDS, LR, and VR. The first draft of the manuscript was written by SDV and VR and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Ethics approval
The Institutional review board of Modena approved the protocol study (protocol n. 1446/15). This trial was registered in ClinicalTrials.gov (Identifier: NCT03747003).
Consent to participate
Written informed consent has been obtained from each participant.
Grants
Supported by the Departments of Excellence Programme of the Italian Ministry of Education, University and Research (MIUR), Italy.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
De Vincentis, S., Greco, C., Fanelli, F. et al. Sarcopenic obesity and reduced BMD in young men living with HIV: body composition and sex steroids interplay. J Endocrinol Invest (2024). https://doi.org/10.1007/s40618-024-02375-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40618-024-02375-6